arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

IDEAYA Biosciences, Inc.

IDYA

$30.67 ▼ -1.67 (-5.18%) at close

10 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

IDEAYA Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B

Dividend Yield —

Revenue Growth 3024.4% ↗

Op. Margin -72.8%

ROIC -12.3% ↗

FCF / Share $-0.83 ↗

Trailing P/E —

Price / Book 2.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$218.71M

↑ +3024.4% —

Net Income Profit after all expenses

$-113.70M

↑ +58.6% —

Operating Margin Operating profit as % of sales

-72.8%

↑ +40.6% 3th

FCF / Share Free cash flow per share

$-0.83

↑ +73.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	3024.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+37705%)	-70.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-976%)	-54.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-776%)	82.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+929%)	43.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+438%)	—	—	—	—	—
EPS Growth YoY (%)	61.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-71.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-38.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-0.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	58.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-143.0% Weak ↓ Weak Declining Year-over-year change in net income	-92.6% Weak ↓ Weak Declining Year-over-year change in net income	-17.9% Weak ↓ Weak Declining Year-over-year change in net income	-44.3% Weak ↑ Weak Improving Year-over-year change in net income	17.8% Good ↑ Good Improving Year-over-year change in net income	-22.2% Weak Weak Year-over-year change in net income	-189.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	73.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-50.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	6.5% Fair Fair Year-over-year change in free cash flow	-31.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	62.5% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-37.0% Weak Weak Compound annual revenue growth over 3 years	6.2% Fair Fair Compound annual revenue growth over 3 years	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	62.1% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	-72.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-586%)	—	—	-122.7% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-918%)	-179.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1299%)	-180.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1306%)	—	—	—	—
Profit Margin (%) (%)	-52.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-533%)	—	-483.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4125%)	-115.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1060%)	-178.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1584%)	-176.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1571%)	—	—	—	—
FCF Margin (%) (%)	-33.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-177.9% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-209.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	281.3% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.65x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.54x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	-1.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.18x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-12.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	58.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	72.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-14.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-29.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-37.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-11.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-174%)	-25.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-273%)	-18.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-221%)	-16.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-212%)	-16.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-210%)	-17.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-216%)	-41.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-379%)	70.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+368%)	75.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+402%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Interest Coverage (x)	—	-13079.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1948.25x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1041.70x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-708.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-431.02x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-486.49x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-367.85x Weak Weak Operating income divided by interest expense Optimal: > 5x	-759.89x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-112.83M	$-84.38M	$-157.02M	$-68.63M	$-92.05M	$-72.04M	$-34.07M	$-20.50M	$-5.96M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$2.47	$0.09	$0.41	$1.23	$0.79	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.28	$-3.36	$-1.96	$-1.42	$-1.41	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.83	$-3.08	$-2.04	$-2.19	$-1.66	—	—	—	—	—
Book Value per Share (USD)	$11.65	$12.24	$9.55	$7.25	$7.82	$6.71	$4.94	$-36.65	—	—
Tangible Book Value per Share (USD)	$11.65	$12.24	$9.55	$7.25	$7.82	$6.71	$4.94	$-36.65	—	—
Basic Weighted Avg Shares (shares)	88.49M	81.68M	57.52M	41.44M	35.25M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$607.91M	$643.64M	$505.53M	$338.74M	$205.84M	$249.97M	$94.71M	$85.25M	—	—
Total Equity (USD)	$1.02B	$1.06B	$621.09M	$349.45M	$301.51M	$198.27M	$100.40M	$-48.95M	$-15.74M	$-4.13M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$218.71M	$7.00M	$23.39M	$50.93M	$27.94M	$19.54M	—	—	—	—
Depreciation Expense (USD)	$2.70M	$2.39M	$2.48M	$2.10M	$1.73M	$1.38M	$1.25M	$886.00K	$391.00K	—
Net Income, GAAP (USD)	$-113.70M	$-274.48M	$-112.96M	$-58.66M	$-49.76M	$-34.49M	$-41.98M	$-34.35M	$-11.86M	—
Operating Cash Flow (USD)	$-71.10M	$-247.58M	$-115.22M	$-87.17M	$-55.78M	$55.46M	$-39.31M	$-27.62M	$-12.22M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 37 quarters

IDEAYA Biosciences, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IDYA with peers